On March 6, the U.S. Food and Drug Administration (FDA) announced the approval of Surfaxin (lucinactant) for the prevention of respiratory distress syndrome in premature infants. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder.